Evidence map›Paper›PMID 38279011›Full record

ReviewAnalytical and bioanalytical chemistry2024

The sensor applications for prostate and lung cancer biomarkers in terms of electrochemical analysis.

Nadia Bounoua, Ahmet Cetinkaya, Ensar Piskin, S Irem Kaya, Sibel A Ozkan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Analytical and bioanalytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. MXene and prostate cancer: is there promising news?Nanomedicine (London, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nadia BounouaDepartment of Exact Sciences, Laboratory of the Innovation Sponsorship and the Emerging Institution for Graduates of Higher Education of Sustainable Development and Dealing with Emerging Conditions, Normal Higher School of Bechar, Bechar, Algeria.
Ahmet CetinkayaDepartment of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
Ensar PiskinDepartment of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
S Irem KayaDepartment of Analytical Chemistry, Gulhane Faculty of Pharmacy, University of Health Sciences, Ankara, Turkey. ikaya19.07@hotmail.com.
Sibel A OzkanDepartment of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey. ozkan@pharmacy.ankara.edu.tr.ORCID http://orcid.org/0000-0001-7494-3077

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate and lung cancers are the most common types of cancer and affect a large part of the population around the world, causing deaths. Therefore, the rapid identification of cancer can profoundly impact reducing cancer-related death rates and protecting human lives. Significant resources have been dedicated to investigating new methods for early disease detection. Cancer biomarkers encompass various biochemical entities, including nucleic acids, proteins, sugars, small metabolites, cytogenetic and cytokinetic parameters, and whole tumor cells in bodily fluids. These tools can be utilized for various purposes, such as risk assessment, diagnosis, prognosis, treatment efficacy, toxicity evaluation, and predicting a return. Due to these versatile and critical purposes, there are widespread studies on the development of new, sensitive, and selective approaches for the determination of cancer biomarkers. This review illustrates the significant lung and prostate cancer biomarkers and their determination utilizing electrochemical sensors, which have the advantage of improved sensitivity, low cost, and simple analysis. Additionally, approaches such as improving sensitivity with nanomaterials and ensuring selectivity with MIPs are used to increase the performance of the sensor. This review aims to overview the most recent electrochemical biosensor applications for determining vital biomarkers of prostate and lung cancers in terms of nanobiosensors and molecularly imprinted polymer (MIP)-based biosensors.

Indexed as

Lung NeoplasmsMolecular ImprintingBiomarkers, TumorElectrochemical TechniquesHumansLungMaleProstateBiomarkers, TumorBiomarkerLung cancerMIPProstate cancerSensor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.